XML 61 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of significant accounting policies - Liability for Sale of Future Royalties (Details)
$ in Thousands
 12 Months Ended
Oct. 18, 2023
USD ($)
Option
Jul. 17, 2020
USD ($)
Dec. 31, 2023
USD ($)
Assigned royalty payments      
Cash consideration received from Royalty Purchase Agreement     $ 1,000,000
Assigned royalty payment, retained percentage   57.067%  
Remaining potential milestones that can be achieved     $ 150,000
Effective interest rate of the liability component     10.80%
Loss on extinguishment of debt     $ 137,558
Aggregate Royalty Purchase Agreements | Royalty Pharma      
Assigned royalty payments      
Total percentage of royalty rights assigned 80.9777%    
Original Royalty Purchase Agreement      
Assigned royalty payments      
Assigned royalty payment, percentage   42.933%  
Cash consideration received from Royalty Purchase Agreement   $ 650,000  
Royalty purchase agreement termination period once there are no further royalty payment obligations   60 days  
Royalty purchase agreement, payment maximum $ 1,300,000 $ 1,300,000  
Original Royalty Purchase Agreement | Royalty Pharma      
Assigned royalty payments      
Royalty purchase agreement, payment maximum 1,300,000    
A&R Royalty Purchase Agreement      
Assigned royalty payments      
Cash consideration received from Royalty Purchase Agreement $ 1,000,000    
Royalty purchase agreement termination period once there are no further royalty payment obligations 60 days    
Effective interest rate of the liability component 10.80%    
Retained Royalty Rights percentage sold 38.0447%    
Percentage of total royalty payable after threshold royalties received 66.6667%    
Additional cash consideration $ 500,000    
Number of put options held by the company | Option 5    
Maximum number of put options which can be exercised before Royalty Pharma can exercise a call option | Option 2    
Maximum percentage of remaining retained royalty rights that are available upon exercise of call option 50.00%    
Fair value of liability for sale of future royalties. $ 1,809,900    
Loss on extinguishment of debt $ 44,900    
A&R Royalty Purchase Agreement | Royalty Pharma      
Assigned royalty payments      
Percentage of maximum royalty payable until assigned royalty rights 90.4888%    
Percentage of maximum royalty payable thereafter assigned royalty rights 83.3333%